From osteoarthritis treatments to future regenerative therapies for cartilage.
Osteoarthritis (OA) is associated with cartilage degeneration and an accompanying inflammatory syndrome of the synovium in addition to alteration of the subchondral bone. The molecular and cellular events involved in OA have only partially been elucidated. This review provides a global view of the physiopathology of OA, as well as non-pharmacological and pharmacological treatments for the disorder. An update on surgical treatments and their indications is given with an orientation towards the management of OA and cartilage repair by cell-based regenerative therapies. These promising biological technologies will, potentially, play a major role in the treatment of cartilage-associated diseases.
Clouet
Johann
J
INSERM (Institut National de la Santé et de la Recherche Médicale), U791, Centre for Osteoarticular and Dental Tissue Engineering, Group Physiopathology of Skeletal Tissues and Cartilage Engineering, University of Nantes, France.
Vinatier
Claire
C
Merceron
Christophe
C
Pot-vaucel
Marianne
M
Maugars
Yves
Y
Weiss
Pierre
P
Grimandi
Gaël
G
Guicheux
Jérôme
J
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001174:Arthrodesis; D019643:Arthroplasty, Replacement; D002358:Cartilage, Articular / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery*; D017690:Cell Transplantation; D015316:Genetic Therapy; D006801:Humans; D019637:Orthopedic Procedures; D010003:Osteoarthritis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D010027:Osteotomy; D012038:Regeneration / Q000187:drug effects* / Q000235:genetics; D023822:Tissue Engineering / Q000379:methods; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents